scholarly journals A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

2012 ◽  
Vol 23 (1) ◽  
pp. 46-52 ◽  
Author(s):  
A.J. Zurita ◽  
E. Jonasch ◽  
X. Wang ◽  
M. Khajavi ◽  
S. Yan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Angiogenic Factor ◽  
Sorafenib Therapy ◽  
Selection Of

Activity of retreatment with sorafenib for metastatic renal cell carcinoma.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 404-404 ◽  
Author(s):  
M. Nozawa ◽  
N. Matsumura ◽  
M. Yasuda ◽  
Y. Okuda ◽  
H. Uemura
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Benefit ◽  
Renal Cell ◽  
Objective Response ◽  
Interleukin 2 ◽  
Severe Toxicity ◽  
Sorafenib Therapy ◽  
Significant Difference

404 Background: Treatment options for metastatic renal cell carcinoma (mRCC) have increased. Complete remission is, however, rarely seen and patients are treated with multiple sequential therapies. We assessed clinical activity of sorafenib rechallenge after progressing on other therapies. Methods: Patients with mRCC who received a second course of sorafenib therapy after failure of prior sorafenib and other agents were retrospectively identified. RECIST-defined objective response rate and progression-free survival (PFS) and toxicity were analyzed. Results: Fourteen patients with mRCC who were retreated with sorafenib were identified and twelve patients were assessable for this study. 92% were male. Median age at first systemic therapy was 63 years. Prior nephrectomy was performed in 92% of patients. 42% of patients had favorable or intermediate risk, 17% poor, and the rest not available per MSKCC criteria. Eighty-three percent of patients were treated with other agents before initial sorafenib therapy, including 75% interferon-alpha (IFN-alpha), 50% interleukin-2 (IL-2), and 17% sunitinib. First sorafenib therapy began a median of 9.0 months after the diagnosis of mRCC and produced a clinical benefit (PR + SD) rate of 75% and a median PFS of 5.0 months. 67% of patients discontinued initial sorafenib for disease progression and 33% for adverse events. Interval between discontinuation of initial sorafenib and rechallenge was a median of 7.6 months. During the intervening period, 50% of patients were treated with sunitinib, 33% with everolimus, 25% with VEGFR1 vaccine, and others. Clinical benefit rate of 67% and a median PFS of 4.3 months were obtained on sorafenib rechallenge. There was no significant difference in outcome to sorafenib rechallenge based on duration between sorafenib treatments or number or type of intervening treatments. No new severe toxicity was observed during rechallenge. Conclusions: Sorafenib rechallenge has potential to achieve clinical benefits, is well-tolerated, and may be considered after multiple sequential therapies in select mRCC patients. No significant financial relationships to disclose.

Subcutaneous Interleukin-2 and Interferon in metastatic renal cell carcinoma: Our experience

1996 ◽  
Vol 63 (4) ◽  
pp. 467-475
Author(s):  
T. Franceschi ◽  
M.A. Bassetto ◽  
F. Pasini ◽  
R. Nortilli ◽  
G. Cetto
Keyword(s):  
Renal Cell Carcinoma ◽  
Partial Response ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Interleukin 2 ◽  
Good Prognosis ◽  
Hematological Toxicity ◽  
Selection Of

Low-dose subcutaneous Interleukin-2 (IL-2), alone or in combination with Interferon (IFN), is an active regimen in metastatic renal cell carcinoma. Efficacy is comparable to higher-dose continuous intravenous infusion and toxicity is much lower. However response rate is only 15-25%. In our experience the results obtained with the combination of IL-2 + IFN were disappointing: of the 15 treated patients, only one had a brief partial response. These poor results may be ascribed to the protocol used and the selection of patients. On the other hand, the best published reports in literature with the combination of IL-2 + IFN have showed poor results in “poor prognosis” patients. Chemo-immunotherapeutic regimens have been proposed; however the association of IL-2 + IFN + 5-fluorouracil obtained promising results only in “good prognosis” patients. Based on preclinical studies, we treated 7 patients with unfavourable prognosis features with a combination of IL-2 + IFN + doxorubicin. With severe hematological toxicity, we obtained one partial response and two stable disease, lasting a mean of 14 months. Though preliminary, this finding seems encouraging because it was obtained in poor prognosis patients.

scholarly journals An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma

2012 ◽  
Vol 5 (2) ◽  
pp. 121-128 ◽  
Author(s):  
Maxine Sun ◽  
Shahrokh F. Shariat ◽  
Quoc-Dien Trinh ◽  
Malek Meskawi ◽  
Marco Bianchi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Evidence Based ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document